Search Scholars Central
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
Advanced searchHide advanced search
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Short communication · 8 Jan 2024 Conference abstract · 20 Oct 2014 Merging anticancer metallodrugs and phototherapy: Light activation of ruthenium-based anticancer prodrugs
between cisplatin-like therapies and photodynamic therapy by addressing the light activation of anticancer metallodrugs. A rather vast family of new compounds, based notably on ruthenium(II), change their chemical…
Conference abstract · 15 Oct 2013 On the field of metallodrugs -new ruthenium compounds as anti-tumor agents
chemoresistance. We have been working on the mode of action of these prospective metallodrugs, the possibility of drug distribution through the blood by means of serum protein binding (namely human
Article · 3 May 2019 Metal Based Drugs: Current Use and Future Potential
Besides the remarkable therapeutic success of anticancer drugs such as cisplatin, carboplatin and oxaliplatin, metallodrugs have also shown promising results in the treatment of diseases other than cancer. They have
Conference abstract · 13 Mar 2017 Therapeutic potential against metastatic melanoma of a copper-based aquaporin inhibitor nanoformulated
development of selective AQP inhibitors represents an alternative therapeutic strategy for these pathologies. Metallodrugs of copper and gold are potential candidates to fulfill this need. However, to promote a…
Review article · 2017 Progress in Copper Complexes as Anticancer Agents
clinical success of cisplatin has stimulated the quest for novel anticancer metallodrugs during the last two decades. A major emphasis has been put on copper due to its selective cytotoxicity
Conference abstract · 2017 Therapeutic potential against metastatic melanoma of a copper-based aquaporin inhibitor nanoformulated
development of selective AQP inhibitors represents an alternative therapeutic strategy for these pathologies. Metallodrugs of copper and gold are potential candidates to fulfill this need. However, to promote a…
Conference abstract · 16 Jun 2016 Ruthenium Organometallic compounds as promising anti-metastatic drugs for breast cancer chemotherapy
Ruthenium complexes are the most widely studied non-platinum metallodrugs and hold great potential as alternatives in cancer therapy. During the recent years our group has been putting a significant ... cisplatin…
Conference abstract · 19 May 2016 An investigation on the effect of novel rhenium compounds on breast, prostate, leukemic and brain cancer cell lines
will develop cancer at some point in their lifetime. Cisplatin, carboplatin, oxaliplatin and related metallodrugs are extensively being used in the treatment of a variety of cancers. Unfortunately these drugs…
Conference abstract Resonant X-ray emission spectroscopy for analysis of platinum anti-cancer complexes and their interaction with biomolecules
clinical introduction in the 1970s paved the way for the use of platinum based metallodrugs in chemotherapy. Second-generation analogues (e.g. carboplatin) were discovered shortly after. However, the clinical…
Conference abstract · 30 Mar 2021 Targeting cancer with selective and potent ruthenium compounds
that involved spectroscopic, imaging and proteomic techniques, we show that this family of ruthenium metallodrugs possess very attractive features. Conclusion & Significance: These compounds show high cytotoxicity…
Conference abstract · 2019 Targeting cancer with selective and potent ruthenium compounds
that involved spectroscopic, imaging and proteomic techniques, we show that this family of ruthenium metallodrugs possess very attractive features. Conclusion & Significance: These compounds show high cytotoxicity…
Conference abstract · 24 Apr 2017 Optimizing conventional breast cancer chemotherapy using combinations of nano-drug delivery systems
improving their targeting and uptake into cells. Cisplatin, cis-diamminedichloridoplatinum (II), is the leading metallodrug used in the systemic treatment of solid tumors. Its clinical use is limited by severe
Conference abstract · 20 Jul 2016 Coupling of micro-electrochemical reaction cell to Electrospray MS (EC-ESI MS) for investigation of redox reaction products of cytotoxic metallocomplexes
varied redox potential applied in EC have been studied by ESI MS. The metallodrug analysis was performed in a buffered solution of ammonium formate at the physiological pH of blood
Review article · 7 Jul 2016 Pharmacological Activity of a Few Transition Metal Complexes: A Short Review
part, the nitrogen, oxygen and sulfur donor ligands chelating to transition metals used in metallodrugs are described. The second part describes the pre-clinical screenings viz., anti-microbial, anti-inflammatory
Conference abstract · 13 Jun 2016 New ruthenium phthalocyanines in modulation of nitric oxide and singlet oxygen release: Physical chemical characterizations and improvement of cytotoxicity with liposomes against cancer cells
metallodrugs has been successfully employed against certain tumors. New compounds, structural modifications, drug delivery systems and alternative cancer therapies as Photodynamic therapy (PDT), has been used to improve…
Conference abstract · 8 Dec 2014 Tracking anti-tumor drugs: Ruthenium(II)-cyclopentadienyl complexes as promising agents
cisplatin against several cancer cell lines of typically low, medium and high resistance to metallodrugs, namely ovarian, breast, colon and prostate human tumors (A2780, MCF7, MDAMB231, HT29 and PC3 cell
Conference abstract · 20 Oct 2014 Ruthenium-based anti-cancer compounds: Insights into their uptake mechanisms and cellular targets
structurally related Ru(η5-C5H5) complexes with bidentate N,N´-heteroaromatic ligands as prospective metallodrugs, with focus on exploring the uptake, cell death mechanisms and potential cellular targets. These complexes

